US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
TWI249401B
(en)
*
|
1999-04-14 |
2006-02-21 |
Takeda Chemical Industries Ltd |
Agent for improving ketosis
|
AR030379A1
(es)
*
|
2000-08-22 |
2003-08-20 |
Novartis Ag |
Combinaciones
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US7199102B2
(en)
*
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
DE50111751D1
(de)
*
|
2000-12-21 |
2007-02-08 |
Sanofi Aventis Deutschland |
Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
|
US7025985B2
(en)
*
|
2001-05-28 |
2006-04-11 |
Kanebo, Ltd. |
Dihydroxyphenyl compounds and glucoside compounds thereof
|
CN1512878A
(zh)
*
|
2001-05-28 |
2004-07-14 |
钟纺株式会社 |
脂肪分解促进剂及含有该成分的皮肤化妆原料、饮食品合成物及瘦身方法和用途
|
US6987123B2
(en)
|
2001-07-26 |
2006-01-17 |
Cadila Healthcare Limited |
Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
|
ES2443642T3
(es)
|
2001-09-14 |
2014-02-20 |
Amgen Inc. |
Compuestos de biarilo conectados
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
TW200810743A
(en)
*
|
2002-03-22 |
2008-03-01 |
Novartis Ag |
Combination of organic compounds
|
US6716842B2
(en)
|
2002-04-05 |
2004-04-06 |
Warner-Lambert Company, Llc |
Antidiabetic agents
|
WO2003088962A1
(en)
*
|
2002-04-16 |
2003-10-30 |
Merck & Co., Inc. |
Combination therapy using a ppar alpha/gamma agonist
|
ITMI20021012A1
(it)
*
|
2002-05-13 |
2003-11-13 |
Giovanni Scaramuzzino |
Combinazione di un inibitore dell'enzima hmg-coa reduttasi e di un estere nitrato
|
EP1388352A1
(en)
*
|
2002-08-08 |
2004-02-11 |
Laboratoires Fournier S.A. |
Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
|
EP1546142A4
(en)
*
|
2002-08-29 |
2007-10-17 |
Merck & Co Inc |
INDOLES HAVING ANTIDIABETIC EFFECT
|
PT1537078E
(pt)
|
2002-08-29 |
2010-06-18 |
Merck Sharp & Dohme |
Indoles que possuem actividade antidiabética
|
CA2494601C
(en)
|
2002-09-12 |
2009-09-29 |
F. Hoffmann-La Roche Ag |
N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
|
DE10300099A1
(de)
*
|
2003-01-07 |
2004-07-15 |
Bayer Healthcare Ag |
Indol-Phenylsulfonamid-Derivate
|
JP2006516572A
(ja)
|
2003-01-14 |
2006-07-06 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
代謝モジュレーターとしての1,2,3−トリ置換アリール誘導体および1,2,3−トリ置換ヘテロアリール誘導体ならびにこれらの誘導体に関連する糖尿病および高血糖のような障害の予防および処置
|
WO2004069158A2
(en)
|
2003-01-27 |
2004-08-19 |
Merck & Co., Inc. |
Substituted pyrazoles, compositions containing such compounds and methods of use
|
EA200501607A1
(ru)
*
|
2003-04-14 |
2006-06-30 |
ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи |
Замещённые фенилалкановые кислоты
|
WO2004098510A2
(en)
*
|
2003-04-30 |
2004-11-18 |
Beth Israel Deaconess Medical Center |
Cystic fibrosis therapy
|
MXPA05011524A
(es)
|
2003-04-30 |
2006-03-21 |
Inst For Pharm Discovery Inc |
Acidos carboxilicos sustituidos.
|
US7981915B2
(en)
*
|
2003-04-30 |
2011-07-19 |
Beth Israel Deaconess Medical Center |
Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
|
WO2004100895A2
(en)
*
|
2003-05-13 |
2004-11-25 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
WO2004110368A2
(en)
*
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Combination therapy for the treatment of hypertension
|
WO2004108126A1
(en)
*
|
2003-06-06 |
2004-12-16 |
Snowden Pharmaceuticals, Llc |
Fibric acid derivatives for the treatment of irritable bowel syndrome
|
JP4920410B2
(ja)
|
2003-07-14 |
2012-04-18 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
|
DE10335449A1
(de)
*
|
2003-08-02 |
2005-02-17 |
Bayer Healthcare Ag |
Bicyclische Indolinsulfonamid-Derivate
|
DE10337839A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Bayer Healthcare Ag |
Indolin-Derivate
|
US20050074443A1
(en)
*
|
2003-10-03 |
2005-04-07 |
Treadwell Benjamin V. |
Methods of attenuating autoimmune disease and compositions useful therefor
|
EP1682508A1
(en)
*
|
2003-11-05 |
2006-07-26 |
F. Hoffmann-La Roche Ag |
Phenyl derivatives as ppar agonists
|
WO2005049572A1
(en)
*
|
2003-11-05 |
2005-06-02 |
F. Hoffmann-La Roche Ag |
Benzannelated compounds as ppar activators
|
RU2367659C2
(ru)
*
|
2003-11-05 |
2009-09-20 |
Ф.Хоффманн-Ля Рош Аг |
Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)
|
WO2005056522A2
(en)
|
2003-12-04 |
2005-06-23 |
National Health Research Institutes |
Indole compounds
|
TWI297606B
(en)
*
|
2004-01-16 |
2008-06-11 |
Nat Health Research Institutes |
Cancer therapy
|
EP1744747A4
(en)
*
|
2004-04-26 |
2009-12-02 |
Univ Vanderbilt |
INDIC ACID AND INDULECTIC ACID DERIVATIVES AS THERAPEUTIC ACTIVITIES WITH REDUCED GASTROINTESTINAL TOXICITY
|
US20080076810A1
(en)
*
|
2004-05-28 |
2008-03-27 |
Weiguo Lui |
Benzoureas Having Anti-Diabetic Activity
|
US8022063B2
(en)
*
|
2004-05-29 |
2011-09-20 |
7Tm Pharma A/S |
CRTH2 receptor ligands for medicinal uses
|
MY143599A
(en)
*
|
2004-06-04 |
2011-06-15 |
Merck Sharp & Dohme |
Pyrazole derivatives, compositions containing such compounds and methods of use
|
JP2008505091A
(ja)
|
2004-07-02 |
2008-02-21 |
メルク エンド カムパニー インコーポレーテッド |
抗糖尿病活性を有するインドール
|
EP1773330B1
(en)
|
2004-07-22 |
2010-05-26 |
Merck Sharp & Dohme Corp. |
Substituted pyrazoles, compositions containing such compounds and methods of use
|
AU2005266337A1
(en)
|
2004-07-30 |
2006-02-02 |
Laboratorios Salvat, S.A. |
Tyrosine derivatives as PPAR-gamma-modulators
|
CA2580501A1
(en)
*
|
2004-09-16 |
2006-03-30 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
WO2006055708A2
(en)
*
|
2004-11-18 |
2006-05-26 |
The Institutes For Pharmaceutical Discovery, Llc |
Heterocycle substituted carboxylic acids for the treatment of diabetes
|
WO2006063132A2
(en)
|
2004-12-06 |
2006-06-15 |
The Regents Of The University Of California |
Methods for improving the structure and function of arterioles
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
EP1861382B1
(en)
|
2005-03-04 |
2012-10-10 |
Merck Sharp & Dohme Corp. |
Fused aromatic compounds having anti-diabetic activity
|
EP1890715A4
(en)
*
|
2005-04-29 |
2009-10-28 |
Univ California |
PEPTIDES AND PEPTIDE MIMETICS FOR TREATMENT BY INFLAMMATORY REACTION OF CHARACTERIZED PATHOLOGIES
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
WO2006125651A2
(en)
*
|
2005-05-24 |
2006-11-30 |
Dsm Ip Assets B.V. |
Ligustilide derivatives for the treatment of inflammatory disorders
|
WO2007008501A1
(en)
|
2005-07-06 |
2007-01-18 |
Merck & Co., Inc. |
Antidiabetic oxazolidinediones and thiazolidinediones
|
WO2007015999A2
(en)
|
2005-07-26 |
2007-02-08 |
Merck & Co., Inc. |
Process for synthesizing a substituted pyrazole
|
US20070161006A1
(en)
*
|
2006-01-10 |
2007-07-12 |
Vita Genomics, Inc. |
Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma
|
PE20071221A1
(es)
*
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
EA201101475A1
(ru)
*
|
2006-04-11 |
2012-07-30 |
Арена Фармасьютикалз, Инк. |
Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
|
CN101528222A
(zh)
|
2006-06-19 |
2009-09-09 |
范德比尔特大学 |
用于诊断性和治疗性靶向cox-2的方法和组合物
|
WO2008030604A2
(en)
|
2006-09-08 |
2008-03-13 |
Rhode Island Hospital |
Treatment, prevention, and reversal of alcohol-induced brain disease
|
JP5570223B2
(ja)
|
2007-01-26 |
2014-08-13 |
カネック ファーマ インコーポレイテッド |
タンパク質チロシンホスファターゼ1b(ptp−1b)阻害剤としての縮合芳香族ジフルオロメタンホスホネート
|
AU2008221194B2
(en)
|
2007-02-26 |
2013-06-27 |
Merck Canada Inc. |
Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
|
JP2010526807A
(ja)
|
2007-05-07 |
2010-08-05 |
メルク・シャープ・エンド・ドーム・コーポレイション |
抗糖尿病活性を有する縮合芳香族化合物を用いた治療法
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
WO2009032702A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
US9422363B2
(en)
|
2007-08-28 |
2016-08-23 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
FR2921366B1
(fr)
*
|
2007-09-26 |
2009-12-04 |
Servier Lab |
Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
DE102007054497B3
(de)
*
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
EP2108960A1
(en)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
AU2009314200B2
(en)
|
2008-11-17 |
2011-11-17 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
EP2389226B1
(en)
|
2009-01-23 |
2013-11-20 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
US20110312967A1
(en)
|
2009-01-23 |
2011-12-22 |
Schering Corporation |
Bridged and fused antidiabetic compounds
|
EP2393810A1
(en)
|
2009-02-05 |
2011-12-14 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
CA2768577A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011019538A1
(en)
|
2009-08-13 |
2011-02-17 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
CN102595897A
(zh)
|
2009-09-02 |
2012-07-18 |
默沙东公司 |
作为用于糖尿病的治疗或预防的二肽基肽酶-iv抑制剂的氨基四氢吡喃
|
CN102695414A
(zh)
|
2010-01-15 |
2012-09-26 |
默沙东公司 |
作为抗糖尿病化合物的噁二唑β-咔啉衍生物
|
US8853212B2
(en)
|
2010-02-22 |
2014-10-07 |
Merck Sharp & Dohme Corp |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
|
EP2563764B1
(en)
|
2010-04-26 |
2015-02-25 |
Merck Sharp & Dohme Corp. |
Novel spiropiperidine prolylcarboxypeptidase inhibitors
|
EP2568812B1
(en)
|
2010-05-11 |
2016-10-26 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
US8980929B2
(en)
|
2010-05-21 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
EP2579873A4
(en)
|
2010-06-11 |
2013-11-27 |
Merck Sharp & Dohme |
NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
|
WO2012024183A1
(en)
|
2010-08-18 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
CA2812061A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
CN103347385A
(zh)
|
2010-10-29 |
2013-10-09 |
默沙东公司 |
二醇二氮烯鎓类杂环衍生物
|
EP2665707B1
(en)
|
2011-01-20 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
JO3350B1
(ar)
|
2011-03-07 |
2019-03-13 |
Merck Sharp & Dohme |
مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
|
WO2012138845A1
(en)
|
2011-04-08 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
US9487506B2
(en)
|
2011-04-13 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
US9272987B2
(en)
|
2011-05-02 |
2016-03-01 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate cyclohexyl derivatives
|
US20140088124A1
(en)
|
2011-06-02 |
2014-03-27 |
Robert J. DeVita |
Imidazole derivatives
|
AU2012271009A1
(en)
|
2011-06-16 |
2013-11-14 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
WO2012178142A1
(en)
*
|
2011-06-23 |
2012-12-27 |
Metabolic Solutions Development Company, Llc |
Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases
|
US9422266B2
(en)
|
2011-09-30 |
2016-08-23 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
US9505730B2
(en)
|
2011-10-13 |
2016-11-29 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
EP2768499A4
(en)
|
2011-10-17 |
2015-08-26 |
Univ Vanderbilt |
INDOMETACIN ANALOGUES FOR THE TREATMENT OF CANCER PROSTATE RESISTANT TO CASTRATION
|
US9018200B2
(en)
|
2011-10-24 |
2015-04-28 |
Merck Sharp & Dohme Corp. |
Substituted piperidinyl compounds useful as GPR119 agonists
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
WO2013068328A1
(en)
|
2011-11-07 |
2013-05-16 |
Intervet International B.V. |
Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
|
WO2013068439A1
(en)
|
2011-11-09 |
2013-05-16 |
Intervet International B.V. |
4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
|
AU2012339870B2
(en)
|
2011-11-15 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as GPR119 agonists
|
EP2814485A4
(en)
|
2012-02-17 |
2015-08-26 |
Merck Sharp & Dohme |
DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
|
EP2838906A4
(en)
|
2012-04-16 |
2015-07-15 |
Kaneq Pharma Inc |
FUSED AROMATIC PHOSPHONATE DERIVATIVES AS PRECURSORS OF PTP-1B INHIBITORS
|
EP2874622A4
(en)
|
2012-07-23 |
2015-12-30 |
Merck Sharp & Dohme |
TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
|
WO2014099578A1
(en)
|
2012-12-17 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
|
US9717714B2
(en)
|
2012-12-19 |
2017-08-01 |
Merck Sharp & Dohme Corp. |
Spirocyclic CETP inhibitors
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
US10065945B2
(en)
|
2014-01-24 |
2018-09-04 |
Merck Sharp & Dohme Corp. |
Isoquinoline derivatives as MGAT2 inhibitors
|
WO2016018729A1
(en)
|
2014-07-29 |
2016-02-04 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
CN107074923B
(zh)
|
2014-07-31 |
2021-08-03 |
Uab研究基金会 |
Apoe模拟肽及对清除血浆胆固醇的较高效力
|
WO2016022742A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
EP3177285B1
(en)
|
2014-08-08 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
TW201625672A
(zh)
|
2014-10-24 |
2016-07-16 |
默沙東藥廠 |
升糖素及glp-1受體之共促效劑
|
TW201625635A
(zh)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
|
EP3242666A1
(en)
|
2015-01-06 |
2017-11-15 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
WO2016191334A1
(en)
|
2015-05-27 |
2016-12-01 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
US10213429B2
(en)
|
2015-05-28 |
2019-02-26 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
CN108349891B
(zh)
|
2015-06-22 |
2022-04-05 |
艾尼纳制药公司 |
用于s1p1受体相关病症的化合物的结晶l-精氨酸盐
|
EP3322420B1
(en)
|
2015-07-13 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
WO2017062334A1
(en)
|
2015-10-05 |
2017-04-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
EP3383868B1
(en)
|
2015-11-30 |
2022-10-05 |
Merck Sharp & Dohme LLC |
Aryl sulfonamides as blt1 antagonists
|
US10450309B2
(en)
|
2015-11-30 |
2019-10-22 |
Merch Sharp & Dohme Corp. |
Aryl sulfonamides as BLT1 antagonists
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
WO2017197555A1
(en)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
EP3496715B1
(en)
|
2016-08-15 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
WO2018034918A1
(en)
|
2016-08-15 |
2018-02-22 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
US11008313B2
(en)
|
2016-09-20 |
2021-05-18 |
Merck Sharp & Dohme Corp. |
Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders
|
JP2020500192A
(ja)
|
2016-11-18 |
2020-01-09 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
ジアシルグリセリドo−アシルトランスフェラーゼ2の阻害薬として有用なインドール誘導体
|
WO2018107415A1
(en)
|
2016-12-15 |
2018-06-21 |
Merck Sharp & Dohme Corp. |
Hydroxy isoxazole compounds useful as gpr120 agonists
|
US11534424B2
(en)
|
2017-02-16 |
2022-12-27 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
JOP20190150A1
(ar)
|
2018-06-21 |
2019-12-21 |
Merck Sharp & Dohme |
مركبات مناهضة لـ pcsk9
|
US20220177465A1
(en)
|
2019-04-04 |
2022-06-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
WO2020236690A1
(en)
|
2019-05-22 |
2020-11-26 |
Merck Sharp & Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
EP3972590A4
(en)
|
2019-05-22 |
2023-06-14 |
Merck Sharp & Dohme LLC |
NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USED TO TREAT CARDIOMETABOLIC DISEASES, KIDNEY DISEASES AND DIABETES
|
EP4021919A1
(en)
|
2019-08-30 |
2022-07-06 |
Merck Sharp & Dohme Corp. |
Pcsk9 antagonist compounds
|
EP3842061A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled triazole co-agonists of the glucagon and glp-1 receptors
|
EP3842449A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled olefin co-agonists of the glucagon and glp-1 receptors
|
EP3842060A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled lactam co-agonists of the glucagon and glp-1 receptors
|
WO2021236405A1
(en)
|
2020-05-18 |
2021-11-25 |
Merck Sharp & Dohme Corp. |
Novel diacylglyceride o-acyltransferase 2 inhibitors
|
CA3228604A1
(en)
|
2021-08-19 |
2023-02-23 |
Merck Sharp & Dohme Llc |
Compounds for treating conditions related to pcsk9 activity
|
US20230406885A1
(en)
|
2022-06-15 |
2023-12-21 |
Merck Sharp & Dohme Llc |
Cyclic peptides for trapping interleukin-1 beta
|